- Agreement to perform fill/finish services for approximately 60–90 million doses in the US this year
- Manufacturing will take place at Baxter BioPharma Solutions’ Indiana facility
Baxter International, a global leader in sterile medication production and delivery, and Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that they have entered an agreement for Baxter BioPharma Solutions to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna Covid-19 Vaccine in 2021. Baxter’s BioPharma Solutions business is a premier contract manufacturing organisation that specialises in parenteral (injectable) pharmaceuticals, including vaccines.
“We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for Covid-19,” said Marie Keeley, Baxter BioPharma Solutions vice president. “Baxter is honoured to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.”
The manufacturing of the Moderna Covid-19 vaccine will take place at the BioPharma Solutions fill/finish sterile manufacturing facilities located in Bloomington, Ind. The site has capabilities and expertise in parenteral delivery systems and clinical and commercial vaccine manufacturing, including preventive and seasonal vaccines for global markets. In addition, Bloomington offers a range of production and commercialisation services, including clinical development, formulation, packaging and commercial launch capabilities. Baxter BioPharma Solutions has operated in Bloomington for around 20 years and employs more than 700 individuals on its 600,000ft² campus.
“We welcome the opportunity to work with Baxter BioPharma Solutions on fill/finish manufacturing for the Moderna Covid-19 vaccine in the US,” said Juan Andres, Moderna Chief Technical Operations and Quality Officer. “This additional production will help us continue to scale up our manufacturing capacity in the United States.”
Additional details of the agreement have not been disclosed.